Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
about
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsNevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapySex differences in nevirapine rash.Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsPharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjectsNevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicinSensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patientsTransmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule.Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry.Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compoundsAntiviral therapy for human immunodeficiency virus infectionsPopulation pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults.Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.Investigational reverse transcriptase inhibitors for the treatment of HIV.Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women.Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.Lack of clinically significant drug interactions between nevirapine and buprenorphine.Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapyMultiple peaking phenomena in pharmacokinetic disposition.Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring.Providing Safe and Effective Preventative Antiretroviral Prophylaxis to HIV-exposed Newborns via a Novel Drug Delivery System in Tanzania.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine.Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study.A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.Macrophage Targeted Nanoparticles for Antiretroviral (ARV) Delivery.Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase.Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy
P2860
Q28069383-4B4AC187-22C9-4CA0-B181-88576FD1B7A1Q28367526-93F60362-3FEF-46ED-A901-D052F9AA2D7BQ31704898-2BF4E3AA-0A49-4368-8FB8-D1B80E562855Q33364134-BBA011D5-8BAF-48D2-A55A-63ACF0968569Q33975889-CBE89702-EDEB-4FAB-98F2-E827E68D2740Q34306474-23ECD1D4-E62C-4F9B-A552-66DFE092F78DQ34405883-A7C94627-8CA0-4167-AF4F-E370F5EF8747Q35006387-D8ECEF5D-A56C-4AD7-854D-715A2665D055Q35114874-E557B7CC-D727-4AE8-9C2C-7671E488FD8CQ35123263-23280827-7AD8-429A-97C1-4A344FA259A0Q35123273-60AEE1EE-DC26-4E53-A954-6757CD3A321AQ35366050-77B8A404-A3DB-4406-A216-8625B893FE94Q35804046-1276F14E-64A8-4376-94F3-7AAF44114C0FQ35829744-A72178E6-18A5-4E5A-AC69-DDBC366E1B0DQ35861276-DC4618C6-89DC-48B7-A105-82A7A6FF5274Q36295462-831D0D06-B72C-49AC-B4E4-DB9C5DA85659Q36306231-82F132B9-052B-40B5-B0BF-304DD7FD3599Q36508979-20B7BA8F-9FAB-4E93-953B-0811049977F1Q36676527-8D62F984-E54A-4496-9B6B-523E8EE6E6BDQ37045349-515D0175-E0EC-44A1-84DF-7E5FD6E9D860Q37199040-5E45EA46-FDD9-4B8C-8474-F4283BC22688Q37444323-5552DBF8-D46C-4E4C-967F-4C68AEDD708DQ37688260-B64BF431-BD18-4859-BC96-BD4B4882C919Q37756115-10461540-9A1B-4842-8E4D-710AFAC67E3CQ40075886-7F1458BF-B963-4AE1-9167-C240BE375627Q40668178-274C045F-145E-4AB7-AB6A-88431833A66CQ40772216-A24D9F81-198C-4634-8318-966644C58208Q43467646-DEFE7DEF-BEBB-40C6-9783-46C6F306A7FFQ43956445-3071C7AE-9517-494F-8873-749827ED84E6Q43996453-770FF0A9-D83B-49FE-8F00-2F70778CCC81Q45748524-DA0DBA23-611E-4F82-9444-E55523D40133Q46818292-C756ABD4-8D8F-4210-AFC8-F8A355949CBDQ50327669-808AF410-9DD9-476A-B743-35C2EE6508FEQ51051365-65DCA2B1-2E58-472D-9672-32F5DEE9E4E1Q51064185-DF958EB0-DBC9-4A4B-B9EF-299AF383E82CQ52845326-B5EA4828-B439-4749-9FC7-B0441B6E46F2Q57287116-66012757-37A8-4E1B-80AD-FF190B07E46A
P2860
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
@ast
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
@en
type
label
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
@ast
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
@en
prefLabel
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
@ast
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
@en
P2093
Cheeseman SH
McLaughlin MM
Sullivan JL
P2860
P304
P356
10.1128/AAC.37.2.178
P407
P577
1993-02-01T00:00:00Z